Uveal Melanoma

CARLSBAD, Calif. — Patients with uveal melanoma who had Medicaid or no insurance were less likely to receive brachytherapy and more likely to be diagnosed at later stages, according to a study presented here.

In this Healio Video Perspective, Carol Shields, MD, discusses data investigating Fitzpatrick skin type and uveal melanoma presented at the Retina Society meeting.

Isolated hepatic perfusion conferred superior overall response rates and longer PFS than best alternative care among previously untreated patients with isolated liver metastases from primary uveal melanoma according to study results.

The FDA granted orphan drug designation to IOA-244 for the treatment of uveal melanoma, according to a press release from iOnctura.

The FDA granted de novo classification to the SeCore CDx HLA Sequencing System for use as a companion diagnostic with Kimmtrak for metastatic or unresectable uveal melanoma, according to a Thermo Fisher Scientific press release.

MONTEREY, Calif. — Progress is being made in the advancement of vision-sparing treatments for uveal melanoma, according to Alison Skalet, MD, PhD.

An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.

In patients with class 2 uveal melanoma tumors, predicted metastasis-free survival by a gene expression profile test was shown to be worse than that observed in a cohort study and worse than that reported in the literature.

PHILADELPHIA — In this Healio Video Perspective from the Wills Eye Conference, Carol L. Shields, MD, discusses updates in uveal melanoma.

The FDA approved tebentafusp-tebn for the treatment of adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma.